ASCO: Maintenance therapy for NSCLC

Share :
Published: 18 Jun 2009
Views: 14996
Dr. Vincent A. Miller - MD Memorial Sloan-Kettering Cancer Center, New York, USA
ASCO press conference: A phase III trial finds that adding erlotinib (Tarceva) to bevacizumab-based (Avastin) maintenance therapy in patients with advanced NSCLC delays cancer progression more than maintenance treatment with bevacizumab alone.